Business Context and Reporting Period
This Form 8-K Current Report was filed by AMN Healthcare Services, Inc. on July 2, 2024. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to director compensation:
- Equity Grant: Restricted stock units with an aggregate grant date fair value of approximately $127,500.
- Cash Retainer (Initial): A pro-rata payment of $17,363.76 upon appointment.
- Cash Retainer (Quarterly): Eligibility for a quarterly cash retainer of $22,500 beginning in the fourth quarter of 2024.
Material Changes
The primary material change reported is the increase in the size of the Board of Directors from eight to nine members. This change was voted on by the Board on July 2, 2024, with the new appointment effective July 22, 2024.
Management Commentary and Governance Details
The Board elected Mr. James H. Hinton as a new independent director. Key details regarding his appointment include:
- Term: Expires at the 2025 Annual Meeting of Shareholders.
- Committee Assignments: Appointed to the Talent and Compensation Committee and the Corporate Governance and Compliance Committee.
- Background: Mr. Hinton is an Operating Partner at Welsh, Carson, Anderson, Stowe (joined 2022). Previously, he served as CEO of Baylor Scott & White Health (2017–2021) and held leadership roles at Presbyterian Healthcare Services for 21 years (1983–2016). He also serves on the board of McKesson Corporation.
- Vesting Schedule: The equity grant vests on the earlier of the first anniversary of the grant date or the 2025 Annual Meeting of Shareholders.
Investor Verification Checklist
- Verify the effective date of Mr. Hinton's appointment (July 22, 2024) against the company's official governance calendar.
- Confirm the vesting conditions and potential dilution impact of the $127,500 restricted stock unit grant.
- Review the updated Board composition to ensure the independence status of the new director aligns with NYSE rules.
- Monitor future filings for the actual payment of the quarterly cash retainer in Q4 2024.